- Higher levels of stromal tumor-infiltrating lymphocytes (sTILs) are positive predictors for improved survival in women with early-stage triple-negative breast cancer (TNBC) undergoing anthracycline-based chemotherapy with/without taxanes.
- In node-negative patients with high sTILs (≥30%), 3-year OS reaches 99%.
Why this matters
- Findings support a prognostic model for TNBC that can be obtained at https://www.tilsinbreastcancer.org/.
- Pooled analysis of individual data from 9 studies (randomized controlled trials and retrospective cohorts) of 2148 women with TNBC.
- sTILs were obtained at diagnosis before anthracycline-based chemotherapy±taxanes.
- Primary outcome: invasive DFS.
- Funding: Ligue Nationale Contre Le Cancer; International Breast Cancer Study Group.
- 77% of patients had ≥1% sTILs; mean sTILs was 23%.
- Median follow-up ranged from 6.58 to 7.15 years, depending on outcome.
- Higher sTILs were associated with improved survival in multivariate analysis, with each 10% increment corresponding to a 14%-17% improvement:
- DFS: HR, 0.86; 95% CI, 0.83-0.90.
- Distant DFS: HR, 0.83; 95% CI, 0.78-0.87.
- OS: HR, 0.83; 95% CI, 0.79-0.88.
- Node-negative TNBC with ≥30% sTILs had a 3-year DFS of 92% (95% CI, 89%-98%), distant DFS of 97% (95% CI, 95%-99%), and OS of 99% (95% CI, 97%-100%).
- Patients treated over the last 10 years not captured.